ZNF776

Summary

ZNF776 (zinc finger protein 776, HGNC:26765) is a protein-coding gene on chromosome 19q13.43, encoding Zinc finger protein 776 (Q68DI1). May be involved in transcriptional regulation.

Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be active in nucleus.

Source: NCBI Gene 284309 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 79 total
• Phenotypes (HPO): 1
• MANE Select transcript: NM_173632

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26765
Approved symbol	ZNF776
Name	zinc finger protein 776
Location	19q13.43
Locus type	gene with protein product
Status	Approved
Aliases	FLJ38288
Ensembl gene	ENSG00000152443
Ensembl biotype	protein_coding
Entrez	284309

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 3 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000317178, ENST00000431353, ENST00000451849, ENST00000473585, ENST00000489376

RefSeq mRNA: 2 — MANE Select: NM_173632 NM_001348007, NM_173632

CCDS: CCDS12962

Canonical transcript exons

ENST00000317178 — 3 exons

Exon	Start	End
ENSE00001648903	57753291	57758148
ENSE00002257496	57746815	57747091
ENSE00003678203	57750785	57750911

Expression profiles

Bgee: expression breadth ubiquitous, 249 present calls, max score 93.07.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.9028 / max 136.6362, expressed in 1783 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
177793	6.8637	1709
177794	5.0390	1613

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endothelial cell	CL:0000115	93.07	gold quality
corpus epididymis	UBERON:0004359	92.00	gold quality
germinal epithelium of ovary	UBERON:0001304	91.38	gold quality
cortical plate	UBERON:0005343	90.90	gold quality
palpebral conjunctiva	UBERON:0001812	90.70	gold quality
mucosa of paranasal sinus	UBERON:0005030	90.24	gold quality
epithelial cell of pancreas	CL:0000083	90.17	gold quality
ganglionic eminence	UBERON:0004023	88.87	gold quality
ventricular zone	UBERON:0003053	88.74	gold quality
pancreatic ductal cell	CL:0002079	88.70	gold quality
seminal vesicle	UBERON:0000998	88.51	gold quality
secondary oocyte	CL:0000655	88.23	gold quality
cardiac muscle of right atrium	UBERON:0003379	88.05	silver quality
thymus	UBERON:0002370	88.00	gold quality
left ventricle myocardium	UBERON:0006566	87.78	silver quality
epithelium of nasopharynx	UBERON:0001951	87.39	gold quality
caput epididymis	UBERON:0004358	87.38	gold quality
pigmented layer of retina	UBERON:0001782	87.21	gold quality
parietal pleura	UBERON:0002400	86.86	gold quality
Brodmann (1909) area 23	UBERON:0013554	86.74	gold quality
ileal mucosa	UBERON:0000331	86.28	gold quality
biceps brachii	UBERON:0001507	86.19	gold quality
sperm	CL:0000019	85.63	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	85.51	gold quality
deltoid	UBERON:0001476	85.16	silver quality
oocyte	CL:0000023	85.06	gold quality
visceral pleura	UBERON:0002401	84.96	gold quality
bone marrow	UBERON:0002371	84.58	gold quality
vastus lateralis	UBERON:0001379	84.44	gold quality
Brodmann (1909) area 46	UBERON:0006483	84.29	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.89
E-MTAB-6058	no	401.60

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

137 targeting ZNF776, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-25-3P	99.98	74.60	1817
HSA-MIR-363-3P	99.98	74.72	1821
HSA-MIR-367-3P	99.98	74.83	1819
HSA-MIR-32-5P	99.98	75.21	1964
HSA-MIR-92A-3P	99.98	75.21	1960
HSA-MIR-92B-3P	99.98	75.25	1955
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-557	99.96	70.01	1640
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-218-5P	99.93	72.22	2103
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-9902	99.89	69.15	2250

Cross-species orthologs

0 orthologs

Paralogs (51): WIZ (ENSG00000011451), ZNF416 (ENSG00000083817), MYNN (ENSG00000085274), PRDM4 (ENSG00000110851), PRDM2 (ENSG00000116731), ZBTB17 (ENSG00000116809), ZNF644 (ENSG00000122482), GZF1 (ENSG00000125812), ZNF426 (ENSG00000130818), ZNF287 (ENSG00000141040), ZNF697 (ENSG00000143067), ZNF687 (ENSG00000143373), ZNF214 (ENSG00000149050), ZNF547 (ENSG00000152433), ZNF230 (ENSG00000159882), ZNF222 (ENSG00000159885), ZNF233 (ENSG00000159915), ZNF333 (ENSG00000160961), ZNF319 (ENSG00000166188), ZNF592 (ENSG00000166716), ZNF646 (ENSG00000167395), ZNF507 (ENSG00000168813), ZNF768 (ENSG00000169957), ZNF417 (ENSG00000173480), ZNF408 (ENSG00000175213), ZBTB41 (ENSG00000177888), ZNF223 (ENSG00000178386), ZNF852 (ENSG00000178917), ZNF784 (ENSG00000179922), ZNF572 (ENSG00000180938), ZNF707 (ENSG00000181135), ZNF746 (ENSG00000181220), ZNF467 (ENSG00000181444), ZNF530 (ENSG00000183647), ZNF17 (ENSG00000186272), ZNF527 (ENSG00000189164), ZKSCAN7 (ENSG00000196345), ZNF34 (ENSG00000196378), ZNF774 (ENSG00000196391), ZNF777 (ENSG00000196453)

Protein

Protein identifiers

Zinc finger protein 776 — Q68DI1 (reviewed: Q68DI1)

All UniProt accessions (3): Q68DI1, C9J7N9, H7C4D2

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

RefSeq proteins (2): NP_001334936, NP_775903* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR050329	GLI_C2H2-zinc-finger	Family

Pfam: PF00096, PF01352

UniProt features (20 total): zinc finger region 11, cross-link 4, sequence conflict 3, chain 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q68DI1-F1	65.93	0.43

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 171, 196, 220, 247

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-212436	Generic Transcription Pathway

MSigDB gene sets: 49 (showing top): LEE_RECENT_THYMIC_EMIGRANT, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, CEBPZ_TARGET_GENES, PRKDC_TARGET_GENES, SIPA1_TARGET_GENES, TERF1_TARGET_GENES, ZBTB12_TARGET_GENES, ZNF197_TARGET_GENES, ZNF766_TARGET_GENES, MIR186_5P, MIR302E, MIR577

GO Biological Process (4): regulation of transcription by RNA polymerase II (GO:0006357), negative regulation of DNA-templated transcription (GO:0045892), positive regulation of transcription by RNA polymerase II (GO:0045944), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (7): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), zinc ion binding (GO:0008270), transcription cis-regulatory region binding (GO:0000976), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RNA Polymerase II Transcription	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	2
transcription by RNA polymerase II	2
DNA-templated transcription	2
regulation of transcription by RNA polymerase II	2
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
negative regulation of RNA biosynthetic process	1
positive regulation of DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
transition metal ion binding	1
transcription regulatory region nucleic acid binding	1
sequence-specific double-stranded DNA binding	1
nucleic acid binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

460 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF776	ZNF148	Q9UQR1	436
ZNF776	ZNF521	Q96K83	408
ZNF776	AKR1E2	Q96JD6	391
ZNF776	ERICH1	Q86X53	380
ZNF776	MSH3	P20585	364
ZNF776	MSH6	P52701	353
ZNF776	EPHB2	P29323	353
ZNF776	FERD3L	Q96RJ6	348
ZNF776	GXYLT1	Q4G148	348
ZNF776	TMEM219	Q86XT9	348
ZNF776	ITLN2	Q8WWU7	348
ZNF776	CPNE4	Q96A23	327
ZNF776	ZNF232	Q9UNY5	324
ZNF776	HSDL2	Q6YN16	310
ZNF776	ZNF853	P0CG23	309

IntAct

8 interactions, top by confidence:

A	B	Type	Score
KRTAP10-6	ZNF776	psi-mi:“MI:0915”(physical association)	0.560
TRIM28	ZNF320	psi-mi:“MI:0914”(association)	0.530
ECE1	ZNF776	psi-mi:“MI:0915”(physical association)	0.370
ZNF776	TRIM24	psi-mi:“MI:0914”(association)	0.350
ZNF776	KRTAP10-6	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (22): ZNF776 (Synthetic Lethality), KRTAP10-6 (Two-hybrid), ZNF776 (Proximity Label-MS), ZNF776 (Proximity Label-MS), ZNF776 (Proximity Label-MS), TRIM24 (Affinity Capture-MS), TRIM33 (Affinity Capture-MS), TRIM39 (Affinity Capture-MS), TRIM28 (Affinity Capture-MS), ZYG11A (Affinity Capture-MS), SIRT5 (Affinity Capture-MS), OPA1 (Affinity Capture-MS), ZNF776 (Affinity Capture-MS), CBX5 (Affinity Capture-MS), ZNF776 (Affinity Capture-MS)

ESM2 similar proteins: A0A087WUV0, A0JNB1, A2VDP4, B2RUI1, P0CG31, P10072, P17025, P17036, P17097, P18733, P51814, Q08ER8, Q09FC8, Q0VGE8, Q14590, Q15937, Q16600, Q2M3X9, Q4V8A8, Q5CZA5, Q5R8G9, Q5RBX0, Q5VIY5, Q68DI1, Q6J6I6, Q6NX49, Q6P1L6, Q6PG37, Q6ZMS4, Q6ZMW2, Q80YP6, Q86UD4, Q86Y25, Q8IZ26, Q8N184, Q8NB42, Q8NEK5, Q8TAF7, Q8TF47, Q8WXB4

Diamond homologs: A2RRD8, A6NFI3, A6NM28, A8MUZ8, A8MWA4, B2RUI1, B4DU55, E9Q8G5, O43296, O43361, O75467, O75820, P0CH99, P0CI00, P10078, P16373, P16374, P17021, P17023, P17032, P17097, P17098, P21506, P51786, P52740, Q06732, Q08ER8, Q13106, Q13360, Q13398, Q14592, Q147U1, Q32M78, Q3KQV3, Q3MIS6, Q3SY52, Q571J5, Q5CZA5, Q5HY98, Q5R7I8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

79 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	65
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

799 predictions. Top by Δscore:

Variant	Effect	Δscore
19:57747447:G:GT	donor_gain	0.9900
19:57747469:GCTT:G	donor_gain	0.9900
19:57750908:CTAGG:C	donor_loss	0.9900
19:57750912:G:GT	donor_loss	0.9900
19:57750913:T:G	donor_loss	0.9900
19:57752556:G:GT	donor_gain	0.9900
19:57752581:A:T	donor_gain	0.9900
19:57746956:GCGC:G	donor_gain	0.9800
19:57747448:A:T	donor_gain	0.9800
19:57747451:G:GT	donor_gain	0.9800
19:57747452:A:T	donor_gain	0.9800
19:57750778:ACG:A	acceptor_gain	0.9800
19:57750780:G:A	acceptor_gain	0.9800
19:57750783:AG:A	acceptor_gain	0.9800
19:57750784:GG:G	acceptor_gain	0.9800
19:57750910:AGGTA:A	donor_loss	0.9800
19:57750911:GGTAA:G	donor_loss	0.9800
19:57750913:TAA:T	donor_loss	0.9800
19:57753285:TTTTA:T	acceptor_loss	0.9800
19:57753286:TTTAG:T	acceptor_loss	0.9800
19:57753287:TTAGG:T	acceptor_loss	0.9800
19:57753288:TAGG:T	acceptor_loss	0.9800
19:57753289:AGG:A	acceptor_loss	0.9800
19:57750775:ATCAC:A	acceptor_gain	0.9700
19:57750779:C:CA	acceptor_gain	0.9700
19:57752572:GGATT:G	donor_gain	0.9700
19:57753289:AGGT:A	acceptor_loss	0.9700
19:57753290:GGTT:G	acceptor_gain	0.9700
19:57747087:CTCAG:C	donor_loss	0.9600
19:57747088:TCAG:T	donor_loss	0.9600

AlphaMissense

3461 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:57754367:T:C	F413L	0.998
19:57754369:T:A	F413L	0.998
19:57754369:T:G	F413L	0.998
19:57754031:T:C	F301L	0.997
19:57754033:T:A	F301L	0.997
19:57754033:T:G	F301L	0.997
19:57754199:T:C	F357L	0.997
19:57754201:T:A	F357L	0.997
19:57754201:T:G	F357L	0.997
19:57754115:T:C	F329L	0.996
19:57754117:T:A	F329L	0.996
19:57754117:T:G	F329L	0.996
19:57754451:T:C	F441L	0.996
19:57754453:T:A	F441L	0.996
19:57754453:T:G	F441L	0.996
19:57754619:T:C	F497L	0.996
19:57754621:T:A	F497L	0.996
19:57754621:T:G	F497L	0.996
19:57754535:T:C	F469L	0.995
19:57754537:T:A	F469L	0.995
19:57754537:T:G	F469L	0.995
19:57754396:C:A	H422Q	0.994
19:57754396:C:G	H422Q	0.994
19:57754480:T:A	H450Q	0.994
19:57754480:T:G	H450Q	0.994
19:57754228:T:A	H366Q	0.993
19:57754228:T:G	H366Q	0.993
19:57754060:T:A	H310Q	0.992
19:57754060:T:G	H310Q	0.992
19:57754065:G:C	R312P	0.992

dbSNP variants (sampled 300 via entrez): RS1000244364 (19:57754892 C>A,T), RS1000576868 (19:57756114 G>A), RS1000638877 (19:57745393 G>A), RS1000806278 (19:57751809 G>A,T), RS1001239999 (19:57755725 C>T), RS1001272722 (19:57755423 T>C), RS1002242352 (19:57757656 G>A), RS1002271592 (19:57749536 G>A,T), RS1002404607 (19:57750485 G>A), RS1002406039 (19:57749202 C>A,T), RS1002957604 (19:57747018 C>T), RS1002988702 (19:57747242 G>A), RS1003096163 (19:57747517 C>A,T), RS1003536961 (19:57747226 C>G), RS1004011824 (19:57758356 G>A)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:209850

GenCC curated gene-disease

Mondo (2): prostate cancer (MONDO:0008315), autism (MONDO:0005260)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000717	Autism

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST002550_25	Allergic rhinitis	5.000000e-08

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

25 total (human), top 25 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression	5
trichostatin A	affects cotreatment, decreases expression	2
Benzo(a)pyrene	affects methylation, increases expression	2
Cyclosporine	decreases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
TAK-243	increases sumoylation	1
beta-lapachone	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	increases methylation	1
jinfukang	affects cotreatment, decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Cisplatin	affects cotreatment, decreases expression	1
Coumestrol	decreases expression	1
Doxorubicin	decreases expression	1
Endosulfan	decreases expression	1
Estradiol	affects expression	1
Ethyl Methanesulfonate	increases expression	1
Formaldehyde	decreases expression	1
Methyl Methanesulfonate	increases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Particulate Matter	decreases expression, increases abundance	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_XW83	HEK293 eGFP-ZNF776	Transformed cell line	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer